Brief: Bergenbio Announces Positive Data From Phase 2 Trial

Oncoinvent ASA

15/02/2023 17:00

Feb 15 (Reuters) - Bergenbio ASA  BGBIO.OL :
    * BERGENBIO ANNOUNCES POSITIVE DATA FROM PHASE 2 TRIAL OF
BEMCENTINIB IN COMBINATION WITH PEMBROLIZUMAB IN 2L+ NSCLC
PATIENTS
    * CLINICALLY MEANINGFUL SURVIVAL BENEFIT AND EVIDENCE OF
DISEASE
CONTROL WAS DEMONSTRATED
    * SIGNIFICANT (P-VALUE < 0.05) AND CLINICALLY MEANINGFUL
IMPROVEMENT IN MOS BASED ON AXL TUMOR PROPORTION SCORE (TPS) WAS
OBSERVED

Source text for Eikon:  ID:nObi3KtJ9a 
Further company coverage:  BGBIO.OL 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))